HELP – cybin inc. (US:NASDAQ)
Stock Stats
News
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder [Yahoo! Finance]
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder
Cybin (HELP) had its price target raised by HC Wainwright from $55.00 to $95.00. They now have a "buy" rating on the stock.
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments [Globe and Mail, The (Toronto, Canada)]
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders [Globe and Mail, The (Toronto, Canada)]
Form 6-K CYBIN INC. For: Mar 05
Form 6-K CYBIN INC. For: Dec 31
Form 6-K CYBIN INC. For: Feb 24
Form 6-K CYBIN INC. For: Feb 18
Form SCHEDULE 13G CYBIN INC. Filed by: ORBIMED ADVISORS LLC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.